Standard
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy : a randomised controlled phase 3 trial. / Coles, Alasdair J; Twyman, Cary L; Arnold, Douglas L; Cohen, Jeffrey A; Confavreux, Christian; Fox, Edward J; Hartung, Hans-Peter; Havrdova, Eva; Selmaj, Krzysztof W; Weiner, Howard L; Miller, Tamara; Fisher, Elizabeth; Sandbrink, Rupert; Lake, Stephen L; Margolin, David H; Oyuela, Pedro; Panzara, Michael A; Compston, D Alastair S; CARE-MS II investigators ; Sørensen, Per Soelberg.
In:
Lancet, Vol. 380, No. 9856, 2012, p. 1829-39.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Coles, AJ, Twyman, CL, Arnold, DL, Cohen, JA, Confavreux, C, Fox, EJ, Hartung, H-P, Havrdova, E, Selmaj, KW, Weiner, HL, Miller, T, Fisher, E, Sandbrink, R, Lake, SL, Margolin, DH, Oyuela, P, Panzara, MA, Compston, DAS, CARE-MS II investigators
& Sørensen, PS 2012, '
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial',
Lancet, vol. 380, no. 9856, pp. 1829-39.
https://doi.org/10.1016/S0140-6736(12)61768-1APA
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Miller, T., Fisher, E., Sandbrink, R., Lake, S. L., Margolin, D. H., Oyuela, P., Panzara, M. A., Compston, D. A. S., CARE-MS II investigators
, & Sørensen, P. S. (2012).
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Lancet,
380(9856), 1829-39.
https://doi.org/10.1016/S0140-6736(12)61768-1Vancouver
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ et al.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Lancet. 2012;380(9856):1829-39.
https://doi.org/10.1016/S0140-6736(12)61768-1Author
Coles, Alasdair J ; Twyman, Cary L ; Arnold, Douglas L ; Cohen, Jeffrey A ; Confavreux, Christian ; Fox, Edward J ; Hartung, Hans-Peter ; Havrdova, Eva ; Selmaj, Krzysztof W ; Weiner, Howard L ; Miller, Tamara ; Fisher, Elizabeth ; Sandbrink, Rupert ; Lake, Stephen L ; Margolin, David H ; Oyuela, Pedro ; Panzara, Michael A ; Compston, D Alastair S ; CARE-MS II investigators ; Sørensen, Per Soelberg. / Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy : a randomised controlled phase 3 trial. In: Lancet. 2012 ; Vol. 380, No. 9856. pp. 1829-39.
Bibtex
@article{ccf251f938794250889452b7fcab2307,
title = "Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial",
abstract = "The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.",
author = "Coles, {Alasdair J} and Twyman, {Cary L} and Arnold, {Douglas L} and Cohen, {Jeffrey A} and Christian Confavreux and Fox, {Edward J} and Hans-Peter Hartung and Eva Havrdova and Selmaj, {Krzysztof W} and Weiner, {Howard L} and Tamara Miller and Elizabeth Fisher and Rupert Sandbrink and Lake, {Stephen L} and Margolin, {David H} and Pedro Oyuela and Panzara, {Michael A} and Compston, {D Alastair S} and S{\o}rensen, {Per Soelberg} and S{\o}rensen, {Per Soelberg}",
note = "Copyright {\textcopyright} 2012 Elsevier Ltd. All rights reserved.",
year = "2012",
doi = "10.1016/S0140-6736(12)61768-1",
language = "English",
volume = "380",
pages = "1829--39",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "9856",
}
RIS
TY - JOUR
T1 - Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy
T2 - a randomised controlled phase 3 trial
AU - Coles, Alasdair J
AU - Twyman, Cary L
AU - Arnold, Douglas L
AU - Cohen, Jeffrey A
AU - Confavreux, Christian
AU - Fox, Edward J
AU - Hartung, Hans-Peter
AU - Havrdova, Eva
AU - Selmaj, Krzysztof W
AU - Weiner, Howard L
AU - Miller, Tamara
AU - Fisher, Elizabeth
AU - Sandbrink, Rupert
AU - Lake, Stephen L
AU - Margolin, David H
AU - Oyuela, Pedro
AU - Panzara, Michael A
AU - Compston, D Alastair S
AU - CARE-MS II investigators
AU - Sørensen, Per Soelberg
N1 - Copyright © 2012 Elsevier Ltd. All rights reserved.
PY - 2012
Y1 - 2012
N2 - The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.
AB - The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.
U2 - 10.1016/S0140-6736(12)61768-1
DO - 10.1016/S0140-6736(12)61768-1
M3 - Journal article
VL - 380
SP - 1829
EP - 1839
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9856
ER -
